No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
88 |
4. Check minimum number of eventsNone |
88 |
5. Include endpointsNone |
88 |
6. Filter based on genotype QC (FinnGen only) |
84 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L44
- Name in latin
- Pityriasis rubra pilaris
Similar endpoints
↥List of similar endpoints to
Pityriasis rubra pilaris
based on the number of shared cases.
Similar with more cases:
- Other papulosquamous disorders
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 659 | 274 | 382 |
| Only index persons | 598 | 256 | 342 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.03 | 55.27 | 53.05 |
| Only index persons | 53.38 | 55.70 | 51.65 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 84 | 41 | 43 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 58.75 | 52.06 | 65.12 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 88
- Matched controls
- 880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
114.1
83
*
D05BB02
ATC
acitretin; oral
+∞
51.1
44
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
18.9
39.0
38
34
D07XC01
ATC
betamethasone; topical
18.6
38.0
37
33
L30.9
ICD-10 Finland
Dermatitis, unspecified
11.7
30.9
48
82
D07AC01
ATC
betamethasone; topical
10.5
26.5
63
170
E0000UV, ,
ATC
12.5
26.2
71
220
L04AX03
ATC
methotrexate; systemic
12.4
25.7
31
37
L40.0
ICD-10 Finland
Psoriasis vulgaris
306.6
23.9
23
*
D07AD01
ATC
clobetasol; topical
9.5
22.7
35
57
D07AC13
ATC
mometasone; topical
7.5
20.4
50
132
D07AB08
ATC
desonide; topical
7.3
16.2
30
58
E000001, ,
ATC
6.2
15.8
39
100
D07AB02
ATC
hydrocortisone butyrate; topical
5.5
14.4
48
158
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
13.9
13
*
D05AX52
ATC
calcipotriol, combinations; topical
23.8
13.6
19
10
D02AE01
ATC
carbamide; topical
12.3
12.1
22
23
TQW80
NOMESCO Finland
Local dermatologic skincare
24.0
11.6
16
8
134
Kela drug reimbursment
General erythroderma
+∞
9.5
9
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.6
9.1
20
44
H02AB06
ATC
prednisolone; systemic
3.7
8.1
56
284
E000003, ,
ATC
9.8
7.7
15
18
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
87.1
7.5
8
*
D05AX02
ATC
calcipotriol; topical
33.0
7.3
9
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.8
6.7
17
42
XQ802
NOMESCO Finland
Epicutan test
12.4
6.5
11
10
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
6.3
6
*
E000002, ,
ATC
4.2
6.3
19
54
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
399
5.42
9.85
14.3
9.7
4.31
4.16
e9/l
0.29
65
355
21
63
4.06
6.49
4.3
3.3
—
—
—
0
0
10
10
11.09
5.69
3.4
3.0
56.70
56.10
%
—
10
10
10
10
11.09
5.69
3.2
2.9
4.37
3.15
e9/l
—
10
10
73
505
3.61
5.27
5.4
4.0
14.85
14.74
pmol/l
0.15
63
454
20
67
3.57
5.23
5.5
1.8
252.05
373.45
nmol/l
1.74
20
58
50
292
2.65
4.78
6.6
6.6
1.19
1.21
mmol/l
0.89
41
257
32
150
2.78
4.73
2.0
1.9
2.86
2.97
mg/l
0.11
25
134
9
11
8.96
4.68
1.6
1.5
—
—
—
0
0
11
25
4.87
3.77
1.5
1.6
—
—
—
0
0
70
514
2.77
3.75
5.7
3.8
10.30
10.76
mm/h
0.13
64
470
40
237
2.26
3.40
3.6
2.9
—
—
—
0
0
28
142
2.43
3.40
1.2
1.2
1.22
1.06
u/ml
—
9
42
33
186
2.24
3.12
3.2
2.6
0.20
0.34
e6/l
0.36
26
143
5
5
10.49
3.01
1.0
1.0
—
—
—
0
0
31
179
2.13
2.71
1.7
2.7
365.54
6639.23
umol/l
1.03
26
153
31
180
2.12
2.66
2.2
1.5
1.65
1.29
mmol/l
1.56
23
149
77
633
2.73
2.60
7.1
4.5
1.81
1.88
mu/l
0.16
69
571
45
306
1.96
2.47
3.4
2.5
98.04
99.35
ug/l
0.02
35
279
9
30
3.22
2.22
3.2
1.6
40.78
39.15
u/l
—
9
24
78
662
2.57
2.15
5.9
3.8
1.50
1.27
mmol/l
1.57
70
613
7
21
3.53
2.01
1.0
1.1
—
—
—
0
0
7
21
3.53
2.01
1.0
1.1
—
—
—
0
0
80
700
2.57
1.99
20.4
12.8
17.02
23.41
mg/l
1.22
69
537
74
624
2.17
1.91
6.6
5.5
40.11
39.13
mmol/mol
0.34
66
586
6
17
3.71
1.87
1.2
1.4
—
—
—
0
0
38
263
1.78
1.84
1.7
1.8
84.76
94.11
pmol/l
0.57
22
145
73
617
2.07
1.80
24.7
14.5
13.85
14.68
%
2.27
73
609
22
130
1.92
1.74
1.8
1.7
423.07
441.33
pmol/l
0.11
15
116
5
13
4.01
1.74
1.2
1.3
—
—
—
0
0
29
189
1.80
1.70
5.8
3.4
16.33
8.89
mg/mmol
0.46
20
125
48
363
1.71
1.66
6.9
6.8
9.77
11.38
umol/l
1.09
43
343
5
14
3.72
1.64
2.2
1.4
—
—
—
0
0
19
109
1.95
1.63
1.7
2.3
0.89
0.82
e6/l
0.06
11
66
20
117
1.92
1.62
1.6
1.3
1.21
5.37
u/ml
—
8
45
7
26
2.83
1.61
13.6
7.2
26.31
24.89
mmol/l
—
7
26
0
43
0.00
1.57
0.0
1.6
—
—
—
0
0
80
719
2.24
1.56
22.7
13.8
139.47
139.82
mmol/l
0.47
75
698
7
27
2.73
1.55
1.9
1.1
—
—
—
0
0
6
21
2.99
1.53
2.2
1.3
—
—
—
0
0
79
706
2.16
1.50
6.6
4.6
2.79
2.75
mmol/l
0.13
70
653
78
691
2.13
1.45
5.5
4.2
1.32
1.45
mmol/l
1.77
69
640
80
723
2.17
1.43
23.0
13.8
4.00
3.97
mmol/l
0.38
75
703
78
692
2.12
1.42
6.9
4.2
4.67
4.62
mmol/l
0.15
73
644
9
41
2.33
1.42
1.7
1.5
—
—
—
0
0
44
337
1.61
1.37
7.1
4.9
0.00
0.00
estimate
-0.00
11
60
44
338
1.60
1.35
4.8
3.5
0.00
0.00
estimate
-0.00
11
65
44
339
1.60
1.33
4.9
3.5
0.00
0.00
estimate
—
8
57
82
753
2.30
1.29
27.1
14.7
78.96
77.46
umol/l
0.14
82
753
6
25
2.50
1.26
3.5
2.8
1.08
1.18
%
—
6
25
76
680
1.86
1.17
5.3
4.4
5.94
5.86
mmol/l
0.22
65
630
56
470
1.53
1.07
3.2
2.9
64.69
43.19
u/l
1.30
49
445
9
48
1.97
1.04
3.8
3.3
1.20
1.22
mmol/l
—
9
43
26
186
1.56
1.03
4.0
3.4
0.00
0.00
estimate
—
10
56
16
101
1.71
1.02
2.1
2.4
0.57
2.39
e6/l
—
8
59
24
171
1.55
0.97
2.8
2.9
593.16
992.69
ng/l
1.12
19
147
6
111
0.51
0.91
3.5
1.4
—
—
—
0
0
32
248
1.46
0.87
4.5
3.3
77.13
28.83
ng/l
0.89
23
166
6
31
2.00
0.86
3.3
3.4
24.45
25.17
mmol/l
—
6
31
7
38
1.91
0.75
1.0
1.3
—
—
—
0
0
5
26
1.98
0.72
1.0
1.2
—
—
—
0
0
5
27
1.90
0.69
4.2
4.3
66.94
58.17
%
—
5
27
33
270
1.36
0.63
5.7
3.6
—
—
—
0
0
19
141
1.44
0.63
2.6
2.1
—
—
—
0
0
10
64
1.63
0.61
9.5
7.4
12.49
11.99
kpa
—
10
59
10
64
1.63
0.61
9.5
7.5
5.06
5.13
kpa
—
10
59
0
21
0.00
0.61
0.0
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.5
—
—
—
0
0
0
22
0.00
0.60
0.0
1.8
—
—
—
0
0
11
73
1.58
0.59
7.3
5.5
1.08
1.01
mmol/l
0.46
11
68
17
125
1.45
0.59
1.6
1.3
10.94
38.79
iu/ml
—
5
42
0
23
0.00
0.59
0.0
1.5
—
—
—
0
0
35
302
1.26
0.44
2.3
2.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
62.17
—
0
15
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
5
35
1.45
0.40
1.6
1.3
—
—
—
0
0
5
35
1.45
0.40
2.6
3.3
0.64
1.18
mmol/l
—
5
27
20
236
0.80
0.32
6.1
4.3
21.25
20.61
%
—
10
119
35
312
1.20
0.31
16.4
11.0
1.05
1.23
inr
2.51
14
90
6
81
0.72
0.25
3.0
6.5
—
—
—
0
0
12
97
1.27
0.24
2.3
1.9
—
—
—
0
0
5
37
1.37
0.24
2.6
3.2
4.95
4.97
kpa
—
5
37
5
42
1.20
0.22
1.8
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
0.82
—
0
6
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
2.17
—
0
12
49
463
1.13
0.18
2.6
3.1
—
—
—
0
0
5
68
0.72
0.17
1.4
1.7
—
—
—
0
0
11
119
0.91
0.04
1.5
1.6
—
—
—
0
0
7
72
0.97
-0.00
1.6
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.9
—
130.09
—
0
8
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
7
70
1.00
-0.00
1.6
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
51.00
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
7.20
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
6.91
—
0
8
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
12.73
—
0
6
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
1.14
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
3.18
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint L12_PITYRIASISRUBRA and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_PITYRIASISRUBRA.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_PITYRIASISRUBRA – Pityriasis rubra pilaris
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data